文献速递抗栓抗凝管理药物相互作用

抗栓管理项目优化联合口服抗栓治疗的成效

Management of combined oral antithrombotic therapy by an antithrombotic stewardship program: A prospective study.
PubMed 文献 · Br J Clin Pharmacol · 2022-04-20

在大型教学医院开展前瞻性队列研究,纳入接受口服抗凝药联合一种或两种抗血小板药的住院患者460例,由多学科抗栓管理项目(ASP)主动评估联合抗栓治疗的适宜性。结果显示251例(54.6%)患者至少需要一项干预,最常见为明确并记录联合抗栓治疗的最长疗程而非终身联用(65.5%)。结论认为,设立专门ASP评估联合抗栓治疗可改善抗栓药物的使用与安全性。

要点

  • 超过半数联合抗栓治疗患者需要ASP干预以优化方案
  • 最常见干预是明确并记录联合治疗的最长疗程而非终身使用
  • 其他常见干预包括无适应证时停用抗栓药及调整剂量

核心结论

  • 在联合口服抗栓治疗患者中,超过一半需要ASP干预,实施专门ASP评估可改善抗栓药物使用与安全性。

研究设计与样本

  • 前瞻性队列研究,在大型教学医院开展,纳入接受口服抗凝药联合一种(双联)或两种(三联)血小板聚集抑制剂的住院患者,共460例,历时12个月。

主要发现

  • 460例中251例(54.6%)至少需要一项ASP干预。
  • 最常见干预为明确并记录联合抗栓治疗所需的最长疗程而非终身联用(65.5%)。
  • 其次为因缺乏适当适应证而停用抗栓治疗(19.4%),以及调整剂量(8.1%)。

关键数值与推荐

  • 需至少一项干预的患者比例为251/460(54.6%)。
  • 明确并记录最长疗程的干预占65.5%,缺乏适应证停药的干预占19.4%,剂量调整的干预占8.1%。

临床怎么用

  • 对口服抗凝药联合一种或两种抗血小板药的住院患者,可由多学科抗栓管理团队主动评估联合方案的必要性、疗程与剂量。
  • 重点明确并记录联合抗栓治疗的最长疗程,避免无明确适应证的联合用药与不必要的终身联用。

局限性

  • 为单中心前瞻性队列研究,未设置对照组,研究结果的外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Antithrombotic management initiatives could prevent inappropriate prescribing and improve patient outcomes especially in patients on combined antithrombotic therapy. To investigate this, a multidisciplinary antithrombotic stewardship program (ASP) was implemented in our hospital. The primary aim of this study was to determine the efficacy of this ASP by assessing the number of patients on combined antithrombotic therapy for whom one or more interventions were needed. METHODS: A prospective cohort study in a large teaching hospital was conducted. Hospitalized patients were included who received combined antithrombotic therapy in which an oral anticoagulant was combined with one (double therapy) or two (triple therapy) platelet aggregation inhibitors. The ASP proactively evaluated the appropriateness of this combined antithrombotic therapy. If needed, ASP improved the concerned therapy. Each improvement measurement recommended by the ASP was counted as one intervention. RESULTS: A total of 460 patients were included over a period of 12 months. Of these, 251 (54.6%) patients required at least one intervention from the ASP. The most common interventions were: (1) to define and document the maximum duration of the combined antithrombotic therapy needed instead of lifetime use of the combination (65.5%), (2) to discontinue antithrombotic therapy as the proper indication was lacking (19.4%), and (3) to adjust the dosage (8.1%). CONCLUSION: An intervention was needed in more than half of the patients on combined antithrombotic therapy. Implementation of a dedicated ASP evaluating combined antithrombotic therapy improves the use and safety of antithrombotic medication.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang ZX, Schroeder-Tanka J, Stooker W, et al. Management of combined oral antithrombotic therapy by an antithrombotic stewardship program: A prospective study. Br J Clin Pharmacol. 2022. PMID: 35384015. doi:10.1111/bcp.15346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。